Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.36 |
| ▸ | JAK2 | O60674 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | MELK | Q14680 | 1/20 | 0.33 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16512907 | 1.00 | CHEK1 (0.36) | CHEK1JAK2KCNH2HDAC4HDAC2 | |
| SCHEMBL21785030 | 0.75 | PARP1 (0.43) | HDAC4HDAC2HDAC8 | |
| SCHEMBL22093860 | 0.74 | JAK2 (0.44) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL13139330 | 0.73 | CHEK1 (0.40) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL8348282 | 0.70 | CHEK1 (0.47) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL30016027 | 0.70 | CHEK1 (0.47) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL1727090 | 0.70 | MAPT (0.39) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL13975636 | 0.70 | BTK (0.43) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL611014 | 0.69 | CHEK1 (0.36) | CHEK1JAK2KCNH2RPS6KA3MELK | |
| SCHEMBL24338048 | 0.68 | CHEK1 (0.45) | CHEK1JAK2KCNH2RPS6KA3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015084857-A1 | METHODS OF TREATING AND PREVENTING ALLOANTIBODY DRIVEN CHRONIC GRAFT VERSUS HOST DISEASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |